Business Context and Reporting Period
Company: BioLife Solutions, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: BioLife develops and sells preservation solutions (HypoThermosol and CryoStor) designed to maintain the viability of cellular matter and tissues during freezing, transportation, and storage. The company serves the biotechnology and medical communities, including cell therapy, cord blood banking, and organ transplantation sectors.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2008 | Six Months Ended June 30, 2007 |
|---|---|---|
| Total Revenue | $595,596 | $411,005 |
| Gross Margin | $209,834 (35%) | $234,648 (57%) |
| Operating Loss | $(1,155,305) | $(1,310,095) |
| Net Loss | $(1,308,020) | $(1,344,259) |
| Cash and Cash Equivalents (End of Period) | $87,715 | $707,074 |
| Total Debt (Promissory Notes) | $3,963,127 | $2,750,000 |
| Stockholders' Equity (Deficiency) | $(3,738,318) | $(2,469,790) |
Cash Flow (Six Months Ended June 30, 2008):
- Net cash used in operating activities: $(1,064,389)
- Net cash used in investing activities: $(6,726)
- Net cash provided by financing activities: $1,102,333
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 45% year-over-year (YoY) for the six-month period, driven by a 40% increase in product sales and a significant rise in licensing revenue ($22,500 vs. $1,667).
- Gross Margin Compression: Gross margin percentage declined sharply from 57% to 35%. Cost of product sales increased 119% YoY, attributed to higher production costs at the company's contract manufacturing organization (CMO).
- Expense Reductions: Operating expenses decreased 12% YoY. Sales and marketing expenses dropped 54% due to reduced headcount and travel costs. Research and development expenses increased slightly (10%) due to IP legal fees and headcount.
- Debt Increase: Long-term promissory notes payable to related parties increased by approximately $1.2 million to $3.96 million, reflecting new draws on a Secured Convertible Multi-Draw Term Loan Facility.
- Liquidity Decline: Cash balances decreased significantly from $707,074 in June 2007 to $87,715 in June 2008, despite financing inflows, due to sustained operating losses.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that continued access to the Multi-Draw Term Loan Facility and cash from operations should provide sufficient funds through December 31, 2008. However, the filing includes a "going concern" warning, noting that if additional capital cannot be secured, the company may not be able to continue operations.
- Financing Needs: The company expects to need additional capital to reach sustainable positive cash flow. It is in discussions with investors to increase the Multi-Draw Term loan or secure other financing. There is no assurance that such capital will be available or that terms will not be dilutive.
- Operational Risks: The company experienced delivery delays from its CMO, resulting in back orders. Management is working to minimize future delays. Additionally, an adverse outcome from current litigation is cited as a risk factor.
- Debt Terms: The Multi-Draw Term Loan bears 7% interest and is convertible into equity at 85% of the purchase price of new equity securities in a bona fide financing of at least $2 million. The debt is secured by all company assets.
Investor Verification Checklist
- Debt Covenants and Conversion: Verify the specific terms of the Secured Convertible Multi-Draw Term Loan, particularly the conversion discount (85%) and the trigger for conversion (financing of $2M+), as this poses significant dilution risk.
- CMO Relationship: Assess the stability of the contract manufacturing organization relationship and the impact of recent delivery delays on future revenue recognition.
- Capital Runway: Confirm the company's ability to access the remaining $1.04 million under the current loan facility and the likelihood of securing further funding before December 31, 2008.
- Cost Structure: Monitor the trend in Cost of Product Sales to determine if the 35% gross margin is sustainable or if further margin compression is likely.
- Related Party Transactions: Review the concentration of debt and legal/consulting fees owed to related parties (directors and stockholders) and the potential for conflicts of interest.